Comparison · NCT04356937-deaths
Tocilizumab vs Placebo: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Tocilizumab vs Placebo: deaths from any cause. Trial comparisons, record NCT04356937-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04356937-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0559 | 0.0297 | 0.103 | wilson | |
| Risk in group 2 | 0.0488 | 0.0191 | 0.119 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00712 | -0.0677 | 0.0626 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.15 | 0.364 | 3.61 | log | |
| Odds ratio, group 1 over group 2 | 1.15 | 0.345 | 3.87 | log | |
| Number needed to harm, for one more death from any cause on Tocilizumab than on Placebo | 140 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Tocilizumab | Standard care plus a single dose of tocilizumab (8 mg/kg administered intravenously, not to exceed 800 mg) | 9 | 161 | EG000 |
| Group 2 | Placebo | Standard care plus placebo | 4 | 82 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
0-28 days. An AE is any unfavorable and unintended sign (including an abnormal laboratory finding),symptom, or disease temporally associated with the use of an investigational medicinal product (IMP) or other protocol-imposed intervention, regardless of attribution.
Source ClinicalTrials.gov
Trial
- Title
- Efficacy of Tocilizumab on Patients With COVID-19
- NCT number
- NCT04356937
- Phases
- PHASE3
- Conditions
- SARS-CoV 2
- Interventions
- Tocilizumab, Placebos
- Lead sponsor
- Massachusetts General Hospital
- Results first posted
- 2021-07-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04356937?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04356937-deaths